Medigene AG (HAM:MDG1) Research & Development: €12.65 Mil (TTM As of Jun. 2024)


HAM:MDG1 Medigene AG HAM:MDG1
12 GF Score
Price €0.02
View Full Analysis

What is Medigene AG Research & Development?

Medigene AG HAM:MDG1 12 Research & Development is €12.65 Mil as of Jun. 2024. GuruFocus rates HAM:MDG1 with a GF Score™ of 12/100.

Research & Development is the aggregate amount of research and development expenses during the year. Medigene AG's Research & Development for the six months ended in Jun. 2024 was €6.29 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 was €12.65 Mil.

Medigene AG  (HAM:MDG1) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Medigene AG Research & Development Related Terms

Medigene AG Research & Development Historical Data

* Premium members only.

The historical data trend for Medigene AG's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigene AG Research & Development Chart

Medigene AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.62 22.26 12.80 28.50 11.55

Medigene AG Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.66 24.84 5.19 6.36 6.29
HAM:MDG1
12GF Score
Medigene AG HAM:MDG1
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medigene AG Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €12.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €12.65 Mil mean?
Medigene AG (HAM:MDG1) has a Research & Development of €12.65 Mil as of Jun. 2024. Research and development expense is the total cost for research and development activities. View historical data on Medigene AG and its competitors.
Is Medigene AG's Research & Development too high?
Medigene AG's current Research & Development is €12.65 Mil. Overall, Medigene AG has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Medigene AG's Research & Development compare to VRTX and REGN?
Medigene AG's Research & Development of €12.65 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Medigene AG and its competitors. Medigene AG's current Research & Development is €12.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigene AG stock overvalued right now?
Medigene AG (HAM:MDG1) has a current Research & Development of €12.65 Mil. The current Research & Development is €12.65 Mil. Medigene AG's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Medigene AG (HAM:MDG1), the current Research & Development is €12.65 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medigene AG Business Description

Address Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152
Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.
12GF Score

Get the complete analysis for HAM:MDG1

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.02
Price